Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rovensky

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Annals of the Rheumatic Diseases|August 10, 2010
Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practiceM C van der Goes, J W G Jacobs, M Boers, et al.
Annals of the Rheumatic Diseases|July 31, 2007
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseasesJ N Hoes, J W G Jacobs, M Boers, et al.
Annals of the Rheumatic Diseases|September 19, 2009
Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseasesM C van der Goes, J W G Jacobs, M Boers, et al.
The Journal of Rheumatology|June 17, 2010
Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) databaseJerome Avouac, Ulrich Walker, Alan Tyndall, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Annals of the Rheumatic Diseases|August 10, 2010
Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practiceM C van der Goes, J W G Jacobs, M Boers, et al.
Annals of the Rheumatic Diseases|July 31, 2007
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseasesJ N Hoes, J W G Jacobs, M Boers, et al.
Annals of the Rheumatic Diseases|September 19, 2009
Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseasesM C van der Goes, J W G Jacobs, M Boers, et al.
The Journal of Rheumatology|June 17, 2010
Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) databaseJerome Avouac, Ulrich Walker, Alan Tyndall, et al.
Pageof 6